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Abstract 
Aging is characterized by accumulation of chronic and irreversible oxidative damage, chronic 
inflammation, and organ dysfunction. Superoxide dismutase (SOD) serves as a major enzyme for 
cellular superoxide radical metabolism and physiologically regulates cellular redox balance 
throughout the body. The copper/zinc superoxide dismutase (SOD1)-deficient mice showed 
diverse phenotypes associated with enhanced oxidative damage in whole organs. 
Here, I found that oral treatment with syringaresinol (SYR, also known as lirioresinol B), which 
is the active component in the berries of Korean ginseng (Panax ginseng C.A.Meyer), attenuated 
the age-related changes in Sod1
-/-
 skin. Interestingly, SYR morphologically normalized skin 
atrophy in Sod1
-/-
 mice and promoted fibroblast outgrowth from Sod1
-/-
 skin in vitro. These 
protective effects were mediated by the suppression of matrix metalloproteinase-2 (MMP-2) 
overproduction in Sod1
-/-
 skin, but not by increased collagen expression. SYR also decreased the 
oxidative damage and the phosphorylation of forkhead box O3a (FoxO3a) protein, which was a 
transcriptional factor of MMP-2, in Sod1
-/-
 skin.  
On the other hand, in skin cells, melanin formation is critical factor for not only melanoma but 
also sun burn and so on. Many of antioxidants are used to prevent excessive melanin generation 
because of melanogenesis involves several oxidizing process. However, melanogenesis 
inhibition mechanism by antioxidants is understood insufficiently. 
In this report, I propose that FoxO3a is a key factor for antioxidant-mediated melanogenesis 
inhibition. Inhibition of FoxO3a results in the expression of melanogenic genes and melanin 
levels elevated. The FoxO3a overexpression by vector transfection or activation by PI3K or Akt 
inhibition reversed these events. When FoxO3a nuclear localization sequence harbored, anti-
melanogenic effect was not observed, suggesting that FoxO3a nuclear translocation is pivotal 
factor for the melanogenesis modulation. Under the condition of antioxidants treatment, 
melanogenesis inhibited correspond with FoxO3a activation, and FoxO3a-directed siRNA 
transfection abolishes these effects. These results indicate that FoxO3a acts as an essential factor 
for melanogenesis regulation.  
Because of its response to various environmental stimuli, FoxO3a could be a remarkable target 
for investigating de novo anti-aging pathway and for designing pharmacological anti-aging 
agents. 
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Introduction 
A genetic contribution to aging can be explained by senescence-protective genes, which have 
been defined in long-lived populations. The forkhead/winged helix Class O transcription factors 
(FoxO) transcription factors have been reported as one of longevity genes. FoxO transcription 
factors are widely conserved in various organisms, depict a divergent cellular works that regulate 
expression of genes, such as the regulation of cell death, cell cycle, development, energy 
metabolism, DNA repair, and stress response 
1-5
. Mammalian FoxO family has defined as 
following: FoxO1, FoxO3, FoxO4, and FoxO6. These FoxOs are triggered by diverse 
environmental stimulation, such as cytokines, nutrients, and insulin growth factors (IGFs). 
FoxOs are speculated as an essential factor for prevent aging and age-dependent diseases 
however, their role in skin aging has yet to be determined. The same consensus binding sequence 
is shared by all FoxO proteins and, can act redundantly. Also, distinct FoxO isoforms have 
specific functions induced by their tissue-specific manner of expression 
6,7
. Each FoxO deletion 
mutants in mice model have uncovered specific works of FoxO isoforms 
8
. In case of FoxO1 
deletion mutant is lethal because of vascular development deficiency 
9
. Knockout mice of 
FoxO3a showed early oocyte depletion by age-dependent infertility 
10
. These reports demonstrate 
that the FoxO genes work in various cellular processes and especially, functions of FoxO3a is 
important in age-dependent skin events. 
 Each FoxO family is elaborately modulated by post-translational modifications, which affect 
stability, activity, and cellular localization of protein. FoxO activity is modulated by reactive 
oxygen species 
11
 either by regulating activity of growth factor receptors, serine/threonine 
kinases, tyrosine kinases, and phosphatases or by modulating factors that upstream of FoxO via 
interactions with lipid metabolism 
12-14
. FoxO activity is activated or inhibited by ROS a context-
dependent manner. In case of the phosphoinositide 3-kinase (PI3K)- protein kinase B (PKB) 
pathway activated by hydrogen peroxide, FoxO activity was inhibited by insulin-mimetic effects 
15
, meanwhile ROS-activated MST1, MAPK, and JNK activate the FoxO proteins 
phosphorylates and abolition of binding with 14-3-3 protein 
16-18
. These results represent that 
ROS signaling and ROS accumulation level regulates FoxO activity positively or also negatively. 
my previous studies have demonstrated that Sod1-deficient (Sod1
-/-
) mice exhibit increased 
intracellular O2
- 
concentrations and various aging-related organ phenotypes 
19
, such as age-
related macular degeneration 
20
, fatty deposits in the liver 
21,22
, skin atrophy 
23,24
, bone loss and 
fragility 
25,26, the progression of Alzheimer’s disease 27, infertility 28, dry eyes 29,30, and rotator 
cuff degeneration 
31
. These findings suggest that cytoplasmic O2
-
-mediated oxidative damage is 
the primary cause of age-related changes in various tissues. Especially, knock down of Sod1 
related with extracellular matrix related-genes suppression, including procollagen 1a1/Col1a1 
and hyaluronan synthase 2/Has2, as well as up-regulation of extracellular degrading genes such 
as Mmp-1 and Mmp-2, results in epidermal and also dermal atrophy 
24,32
.  
On the other hand, previous reports indicate that FoxO3a is involved in cellular processes in 
response to external stress in the skin cells, however FoxO3a functions in melanocytic cells has 
not yet been uncovered. Melanin is produced as a photo-protector against UV irradiation for the 
skin, which is produced by continual oxidation steps. Many antioxidants have been treated to 
hyperpigmentation because of their oxidative properties 
33
. Additionally, the deficient phototype 
of skin is associated with the low activity of catalase, the main enzyme responsible for degrading 
hydrogen peroxide; patients with this phenotype do not tan well, burn relatively easily, and are at 
a higher risk of skin cancer than those with the high skin phototype 
34
, thereby indicating a tight 
association between melanogenesis and oxidative stress in the skin. However, melanogenesis 
regulation by redox state has not yet been studied precise. Because activity of FoxO3a can be 
modulated by redox state, which in turn regulates melanin production steps, I suppose that the 
melanogenesis shift induced by ROS perturbation may occur by FoxO3a-mediated cell signaling. 
Previously, my reports have shown that syringaresinol (4,4’-(1S,3aR,4S,6aR)-tetrahydro-
1H,3H-furo[3,4-c]furan-1,4-diylbis(2,6-dimethoxyphenol, SYR), isolated from Panax ginseng 
berry pulp, activates sirtuin 1 gene expression, leading to delayed cellular senescence, and its 
effects were dependent on FoxO3a 
35
. In the present study, I suggest that FoxO3a is a novel anti-
melanogenic and anti-aging factor for skin. I investigate the feasibility that treatment with natural 
antioxidants can delay skin aging and pigmentation. I investigated the beneficial effects of SYR 
for age-dependent skin atrophy, as well as the underlying biological mechanism of melanin 
formation.  
 
 
Results 
Positive relationship of FoxO3a with melanogenesis in pigmented melanocytes  
FoxO3a regulates cell cycle which results in environment-specific differentiation in various 
pathways 
36
. Foxo3a has the reaction of keratinocytes to UV irradiation and the senescence of 
dermal fibroblasts in skin cells. First, I investigated the expression levels of FoxO1, FoxO3a, and 
FoxO4 in lightly pigmented (LP), moderately pigmented 
37
, and darkly pigmented (DP) 
melanocytes and melanoma MNT1 cells to clarify whether the FoxO genes are involved in 
melanocyte differentiation (Figure 1a-c). In these pigment-related cells, the expression level of 
FoxO3a was more than 10 fold higher levels than the other FoxO proteins (Figure 1b), and with 
increasing degree of pigmentation its expression levels decreased (Figure 1b-c), suggesting an 
adverse relationship between melanin levels and expression of FoxO3a. I treated the cells with 
the LY294002 and wortmannin, these PI3K inhibitors induce FoxO3a activation, to clarify 
whether FoxO3a is involved in melanogenesis 
38
. FoxO3a significantly localized in the nucleus 
when PI3K inhibitors were applied to primary melanocytes (Figure 1d), melanin levels decreased 
(Figure 1e), and the pigment-related proteins were downregulated, which are tyrosinase (TYR), 
tyrosinase-related protein 1 (TYRP1), and dopachrome tautomerase (dopachrome delta-
isomerase, tyrosine-related protein 2, DCT) (Figure 1f). 
 I induced FoxO3a siRNAs into MNT1 cells, which are highly pigmented human melanoma 
cells with mature stage III and IV melanosomes to identify that Foxo3a is a factor in modulation 
of melanogenesis (Figure 1a). Two different types of FoxO3a-directed siRNAs (si-1 and si-2) 
were used and confirmed that both were functioning properly by qPCR and immunoblot assay 
(Figure 2a and c). When siRNAs against FoxO3a were introduced into cells, the expression of 
melanogenesis-related genes, such as microphthalmia-associated transcription factor (MITF), 
tyrosinase-related protein 1 (TYRP1), dopachrome tautomerase (DCT), and tyrosinase (TYR) 
were upregulated, whereas the expression of stem cell factor (SCF), the SCF receptor (cKit), and 
SRY-related HMG-box (SOX10), which are associated with cell proliferation rather than 
melanogenesis were downregulated (Figure 2a-b). Consistent with the pigment-related genes 
upregulation, the MITF, TYR, TYRP1, and DCT protein levels increased (Figure 2c). In addition, 
compared with control or mock (negative control siRNA)-treated cells, accumulated levels of 
melanin (Figure 2d-e) and tyrosinase activity (Figure 2f) were significantly elevated in Foxo3a 
siRNA-treated cells, indicating that FoxO3a down-regulates pigment-related genes results in 
melanogenesis inhibition. And hence, I investigated the early to late melanogenesis-related genes 
expression. By FoxO3a siRNA treatment, the mRNA levels of paired box transcription factor 
(PAX3), melanoma antigen recognized by T-cells (MART1), endothelin receptor B (EDNRB), 
and p75NTR were increased compared with the BRN2, S100, and NOTCH1 levels were 
downregulated (Figure 3a-b). 
 
FoxO3a nuclear translocation suppress melanogenesis 
FoxO3a functions as transcription factor in downstream of the PI3K-PKB (also called AKT) 
pathway 
39
. The activation of PI3K-PKB pathway reduces FoxO3a nuclear translocation by 
phosphorylation of FoxO3a and its transactivation activity is also suppressed 
40,41
. To induce 
FoxO3a nuclear translocation and activation, I used the well-known PI3K inhibitors LY294002 
and wortmannin 
38
. The melanin levels decreased by 59% (LY294002) and 60.3% (Wortmannin) 
when PI3K inhibitors were applied to cells compared with the untreated groups (Figure 4a-b), 
and the tyrosinase activity was reduced by 57.8% and 54.6%, respectively (Figure 4c). In 
contrast with the results shown for FoxO3a-directed siRNA expression, mRNA expression levels 
of the early stage markers of melanogenesis, such as cKit, scf, sox10, notch1, and brn2, were 
increased and the melanogenesis-related genes tyrosinase, mitf, tyrp1, dct, pax3, and ednrb were 
decreased (Figure 3c-d and 4d-e). The mRNA and protein expression levels of FoxO3a were 
increased by PI3K inhibitors which result in nuclear accumulation of FoxO3a proteins (Figure 
4e-f). The protein expression of MITF, TYR, TYRP1, and DCT were downregulated coincide 
with the nuclear accumulation of FoxO3a, suggesting that the large amount of nuclear FoxO3a 
inhibit melanogenesis (Figure 4f).  
 
FoxO3a nuclear translocation is a critical event in melanogenesis regulation 
As shown above results using FoxO3a siRNA and PI3K inhibitors, FoxO3a expression levels and 
nuclear localization are important in melanin formation; however, it still remains unclear whether 
the FoxO3a expression level or localization is more intensively associated with melanogenesis 
modulation. Therefore I constructed plasmids expressing wild-type FoxO3a (plasmid 1787: HA-
FoxO3a; WT) or deletion mutant in the nuclear localization sequence (NLS), a mandatory region 
for FoxO3a translocation 
42
 (plasmid 8361: FLAG-FoxO3a TM; NLS) to investigate the effect 
on melanogenesis of FoxO3a nuclear translocation. The total level of FoxO3a proteins largely 
increased under both of the wild-type or mutant constructs transfection conditions (Figure 4g, 
lower panel, whole FoxO3a), whereas only under the wild-type over-expression condition, the 
nuclear FoxO3a levels were increased (Figure 4g, upper panel). Moreover in the wild-type-
expressing cells but not the NLS mutant-expressing cells, the melanin levels largely decreased 
(Figure 4h), suggesting that the nuclear translocation is more closely associated with 
melanogenesis rather than the Foxo3a protein levels. Nuclear translocation of FoxO3a results in 
its activation 
12
. In this regards, FoxO3a regulates melanogenesis by its activation via nuclear 
translocation. I next evaluated Akt-directed siRNA or an Akt inhibitor for Akt inhibition to 
clarify that FoxO3a nuclear translocation is the essential factor for regulation of melanogenesis. 
Transfection with FoxO3a-directed siRNA increased melanin production by 114.8%, whereas 
treatment Akt siRNA or Akt inhibitor decreased melanin by 61.7% and 59%, respectively (Figure 
4i). The inhibition of Akt blocked phosphorylation of FoxO3a (Figure 4j), and FoxO3a nuclear 
translocation was greatly increased (Figure 4k). According to these results, I suggest that nuclear 
translocation of FoxO3a by either PI3K or Akt inhibition induces the repression of 
melanogenesis. 
 
Anti-melanogenic activity of antioxidants are mediated by FoxO3a activation 
Many antioxidants have been used to treat skin hyperpigmentation because enzymatic oxidation 
steps occur during melanin synthesis. Vitamin C (Vc), vitamin E, hydroquinone, and N-
acetylcysteine (NAC) have been generally used to decrease melanin levels, and synergetic effects 
of antioxidants have been shown 
43,44
. However, the mechanism of melanogenesis regulation by 
antioxidants has not yet been explored in detail. I first investigated the effects of antioxidants on 
pigmentation, including vitamin C, NAC, and Trolox (a water-soluble derivative of vitamin E) to 
reveal this mechanism. As previously reported 
43
 under certain degree of antioxidant, the melanin 
levels and tyrosinase activity gradually decreased. On the other side, these effects were transient, 
and under concentrations higher than 100 nM, antioxidant treatment induced increasing the 
melanin levels and tyrosinase activity gradually (Figure 5a). Despite of their different structure 
and ROS scavenging activity, antioxidants showed similar inhibition patterns against melanin 
formation. A tyrosinase activity, cell cytotoxicity, and proliferation were not impacted by each 
antioxidant in experimental concentration extent (Figure 6). The mRNA and protein levels of 
tyrosinase and DCT were markedly reduced with 100 nM antioxidant treatment meanwhile, the 
expression of MITF and TYRP1 remained unchanged (Figure 5b-c).  
 In the aging model organism C. elegans, antioxidants induce the nuclear translocation of DAF-
16 (a homolog of Foxo3a) 
37
. I speculated that anti-melanogenic effects of antioxidants triggered 
by FoxO3a nuclear translocation and activation. To confirm my hypothesis, I performed 
immunofluorescence assays for observing FoxO3a localization. The FoxO3a nuclear 
translocation by each antioxidant (Vc, NAC, and Trolox) displayed gradual enrichment up to 100 
nM and a gradual reduction at greater concentrations (Figure 7). I presented that 100 nM of each 
antioxidant showed the greatest anti-melanogenic activity and also the nuclear localization of 
FoxO3a which was the concentration that yielded (Figure 8a). These results indicate that Foxo3a 
nuclear translocation by antioxidant modulate melanogenesis. Endogenous nuclear FoxO3a was 
enriched in antioxidant-treat cells without a change in the total protein levels (Figure 8b-c). Next, 
I performed a time-course experiment for FoxO3a nuclear translocation. FoxO3a translocalized 
to the nucleus by Vc after 2 hours and gradually accumulated with time (Figure 8d). FoxO3a 
nuclear localization is continuous rather than transient and this process arises directly and 
quickly (Figure 8d). Whereas antioxidants induced nuclear translocation of Foxo3a, another 
FoxO protein, FoxO1 translocation did not observed (Figure 9).  
 I pretreated FoxO3a-direct siRNA in MNT1 cells and then applied each antioxidant to certify 
that the FoxO3a activation induces anti-melanogenic effect of antioxidants. FoxO3a siRNA 
induces increasing tyrosinase activity and melanin formation (Figure 10a-c). And as expected, 
increased tyrosinase activity and melanin levels did not reversed by any antioxidant treatment 
(Figure 10a-c) at any dose (Figure 10d). Same as these results, increased melanogenesis did not 
reduced also by PI3K inhibitor treatment (Figure 10e). Even though certain doses of antioxidants 
and wortmannin reduced the FoxO3a siRNA-induced melanin, these were not characteristic 
degrees. These results suggest that antioxidants produce anti-melanogenic effects by FoxO3a 
pathway mediation. 
 
SYR attenuates age-related skin atrophy and oxidative damage in Sod1
-/-
 mice  
In Sod1
-/-
 mice, skin thickness was prominently decreased compared with wild-type mice 
19
. Oral 
treatment with ginseng berry extract (GB) and its bioactive component SYR significantly 
increased skin thicknesses in hairless Sod1
-/-
 mice compared with vehicle-treated Sod1
-/-
 mice 
(Figure 11a, 11b, and 12). The attenuation of age-related skin atrophy was remarkable, especially 
in the dermis. SYR or GB treatment was performed from 6 weeks of age or 16 weeks of age for 
8 weeks. In both conditions, SYR effectively recovered age-related skin atrophy (Figure 11a, 11b, 
and 13), as well as GB (Figure 13 and 14). I also observed the dose-dependent manner of SYR 
and GB in skin thinning at 14-week-old Sod1
-/-
 mice (Figure 13 and 14). These findings 
demonstrated that SYR p.o. treatment significantly improved skin atrophy of hairless Sod1
-/-
 
mice, particularly in the dermis. Because Sod1
-/-
 mice show increased oxidative damage 
compared with wild-type mice, I measured the levels of oxidative damage markers and 
intracellular ROS in the skin region. As expected, SYR administration lowered the levels of lipid 
peroxide marker 8-isoprostane in the skin (Figure 11c) and DCF intensity as intracellular ROS in 
cultured primary fibroblasts (Figure 11d). Next, I investigated the protective effects of SYR 
against skin damage. Organ culture experiments using skin discs demonstrated a markedly lower 
outgrowth capacity in Sod1
-/-
 fibroblasts compared with that in Sod1
+/+
 fibroblasts, indicating that 
the migration and proliferation of the Sod1
-/-
 fibroblasts were impaired (Figure 11e). To analyze 
the protective effects of SYR, I next added SYR to cultures of Sod1
-/-
 skin discs. Although SYR 
treatment did not induce any significant changes in Sod1
+/+
 skin, SYR significantly promoted the 
fibroblast outgrowth capacity in Sod1
-/-
 skin discs (Figure 11e). These findings demonstrated that 
the application of SYR ameliorated both skin atrophy and oxidative damage in Sod1
-/-
 mice. 
 
SYR does not activate collagen synthesis through NF-κB signaling 
In a previous study, I showed that ginsenoside Re from GB inhibit the transcription factor v-rel 
reticuloendotheliosis viral oncogene homolog A (RelA, also known as NF-κB p65), thus 
activating collagen synthesis 
45
. Because SYR is also derived from GB, I investigated whether 
SYR treatment affects NF-κB signaling and procollagen expression. However, SYR treatment 
did not inhibit the elevated phosphorylation of NF-κB in Sod1-/- mice (Figure 15a). In addition, 
SYR treatment did not activate the transcription of procollagen 1a1/Col1a1 (Figure 15b) and did 
not suppress the expression of inflammatory cytokine interleukin-6/Il-6 (Figure 15c), both of 
which were regulated by NF-κB. These results indicated that the protective effects of SYR 
against age-related skin atrophy were independent of the NF-κB signaling pathway.  
 
SYR inhibits MMP-2 expression via FoxO3a dephosphorylation 
Since SYR did not affect collagen synthesis, I explored other pathways that might prevent the 
skin aging process. In my previous work using a human MNT1 melanoma cell line, SYR 
displayed potent antioxidative activity and inhibited skin melanogenesis by activating the 
forkhead box O protein, FoxO3a 
46
. I previously reported that antioxidants induce FoxO3a 
nuclear localization by inhibiting its phosphorylation, which results in its activation 
47
. Therefore, 
I hypothesized that SYR also promotes FoxO3a dephosphorylation in vivo. FoxO3a 
phosphorylation was elevated in Sod1
-/-
 mice, indicating that both FoxO3a nuclear export and 
activation were inhibited, although total expression of FoxO3a was not changed significantly 
(Figure 15a). According to my results, SYR-treated mice had greatly reduced FoxO3a 
phosphorylation compared with vehicle-treated and Sod1
+/+
 mice (Figure 16a). Then, I 
investigated phosphorylated FoxO3a (p-FoxO3a) levels in mouse skin via immunohistochemistry. 
Interestingly, I confirmed that dermal thickness was recovered and that p-FoxO3a expression 
was greatly repressed in Sod1
-/-
 mouse skin following SYR treatment (Figure 15d and 17). 
Although the expression of the SIRT1, which was a FoxO3a downstream-related protein, was not 
markedly changed (Figure 18), SYR treatment clearly inhibited FoxO3a phosphorylation in 
mouse skin (Figures 15a, 15d, and 17). During skin aging, collagen degradation by collagenase is 
a major factor in the decline of skin thickness. Previously, I observed the significant upregulation 
of matrix metalloproteinase-2 (MMP-2), which was a member of the type IV collagenase, in 
Sod1
-/-
 skin 
24
, while others indicated that FoxO3a directly down-regulates MMP-2 expression in 
vascular smooth muscle cells 
48
. Therefore, I hypothesized that SYR-induced FoxO3a 
dephosphorylation affects MMP-2 expression and rescues age-related skin atrophy. I investigated 
MMP-1 and MMP-2 expression in mouse skin via immunohistochemistry. Expectedly, MMP-2 
expression decreased dramatically after SYR treatment (Figure 16a). To confirm this result, I 
also investigated the protein and mRNA expression levels of these proteins in mouse back skin. 
MMP-1 and MMP-2 protein expression was elevated in Sod1
-/-
 mice compared with wild-type 
mice. Intriguingly, only MMP-2 expression was greatly suppressed by SYR treatment (Figure 
16b and 16c), similar to the immunohistochemistry data. Additionally, qRT-PCR analysis also 
revealed a similar pattern as the above data (Figure 16d). Here, I also displayed the 
immunohistochemistry data on MMP-2 expression levels from GB-treated Sod1
-/-
 mice (Figure 
19). According to these data, SYR and GB treatment strongly abrogated MMP-2 expression, 
which was elevated by aging-like processes in mice. These data indicates that SYR treatment 
rescues age-related skin atrophy by inhibiting MMP-2 expression, which is mediated by FoxO3a 
dephosphorylation.  
 
Discussion 
Melanin formation steps include enzymatic oxidation steps in the melanin polymer syntheses and 
engagement. In this regards, many antioxidative reagents have been used to skin 
hyperpigmentation; however, the modulatory mechanism is not clarify in detail. FoxO3a, well-
known anti-aging transcription factor, controls many target genes that are involved in the 
antioxidative response in diverse cell types, including skin cells. In this study, I propose that 
FoxO3a is a novel anti-melanogenic factor by involving melanogenesis regulation. Based on my 
results from FoxO3a knockdown, overexpression and the activation using PI3K inhibitors and 
Akt inhibition, I suggest that FoxO3a is an anti-melanogenic factor. I also demonstrated that 
antioxidants induce anti-melanogenic activity by FoxO3a nuclear translocation, result in its 
activation. 
Anti-melanogenic effect of antioxidants is simply explained by reduced cellular ROS level by 
its ROS scavenging effect. However, melanin synthesis inhibition by antioxidants was not dose-
dependent event. According to my results, FoxO3a activation by antioxidants has good 
coordination with its anti-melanogenic effect (Figure 8 and 10), giving a reasonable molecular 
mechanism. I detected that the tyrosinase activity and also melanin levels were reduced to a 
certain extent in response to antioxidant treatments; the maximum efficacy was presented at 100 
nM, and higher doses showed lowered effects. These anti-melanogenic effects were well 
coordinated with the FoxO3a nuclear translocation (Figure 5 and 7-8). Hermetic (bell-shaped or 
U-shaped) concentration efficacy curves are often observed for many chemicals, including drugs, 
toxins, oxidants, and antioxidants 
49
. FoxOs are assumed as key players in redox signaling 
because they transcript ROS-scavenging enzymes and, adversely, its activities are post-
translationally regulated by oxidative stress 
50
. As previously reported, the FoxO cysteine 
residues have been reported to be involved in the interaction with nuclear import receptor 
transportin-1 through disulfide formation and act as sensors for the local redox state. The nuclear 
translocation of FoxO regulated through varying stability and interaction aspect induced by 
different redox states 
51
. This finding may give a hint about concentration higher than 100 nM 
rather reduce FoxO3a nuclear translocation. The reduced anti-melanogenic effects of antioxidant 
at high concentrations may explained by cellular defense mechanisms against hyper-reductive 
conditions. After sensing a hyper-reductive state for the oxidative and reductive states balance, 
then cells activate a re-oxidation signaling evoked by the FoxO protein. A hyper-reductive state 
inside cells was induced by high levels of antioxidants, and then reduces FoxO nuclear 
translocation by which inhibitions disulfide formation with binding partners. 
FoxO3a overexpression or activation affected the expression of melanogenesis-related genes, 
MITF, tyrosinase, TYRP-1, and DCT (Figure 4). On the other hand, FoxO3a activation by 
antioxidants seems to selectively affect the expression of tyrosinase and DCT among them 
(Figure 5). Furthermore, antioxidants and PI3K inhibitors could not recover the elevated melanin 
synthesis caused by the FoxO3a siRNA pre-treatment (Figure 10). These results indicate that 
FoxO3a pathway is a key factor for modulation of melanogenesis-related genes by antioxidant-
mediated melanogenesis regulation. 
In my study, FoxO3a was proven to be an essential factor for the melanogenesis regulation. 
There are still many of unsolved questions remains unknown such as the mechanism by which 
FoxO3a regulates many melanogenic genes. Generally, many proteins exist which interacts and 
forms a complex with FoxO3a, there is a possibility of binding and generating high molecular 
weight complexes and perform functions that are associated with melanogenesis in the nucleus. 
The FoxOs contain one forkhead-binding domain fused with the transcriptional activation 
domain. FoxOs generate a chimeric form by interaction with forkhead-binding domain and the 
DNA-binding domain of other transcription factors 
52
. In the previous study, the PAX3-FoxO1 
chimeric form has been found in alveolar rhabdomyosarcoma and consists of the transactivation 
and DNA-binding domains of FoxO1 and PAX3, respectively 
53
, suggesting that FoxO3a may 
also interact with PAX3. Peroxisome proliferator-activated receptor (PPAR) gamma coactivator 
(PGC)-1α could be another possible binding target of FoxO3a. PGC-1α is regulated by alpha-
melanocyte stimulating hormone (α-MSH) and activates MITF in human melanoma cell lines 54. 
According to previous report, FoxOs regulate PGC-1α transcriptionally and post-translationally 
and they can co-operate with each other 
55
. In my results, PAX3 and MITF mRNA levels 
upregulated by deletion of FoxO3a using siRNA and FoxO3a activation by PI3K inhibitors 
reversed this effect. Considering my results, PAX3 and PGC-1α do not seem to be direct 
transcriptional binding targets of FoxO3a. However, these melanogenic factors still have 
potential for FoxO3a binding partners in melanogenesis modulation. I also suppose that other 
melanogenesis-related proteins, such as SCF, cKit, and SOX10, for which their expression levels 
were influenced with FoxO3a modulation, could be transcriptional targets of FoxO3a.  
 In skin hyperpigmentation and melanoma, operating ROS production or the activity of cellular 
regulators has been thought as an attractive therapeutic target for inhibiting melanogenesis. 
Typically, in order to reduce melanin synthesis, pharmacological agents primarily focused on 
eliminating ROS via the antioxidative process. Based on my present study, an anti-melanogenic 
effect of antioxidants mediates FoxO3a. Because FoxO3a is related with longevity in many aging 
model organisms, this study suggests that FoxO3 could be a potent target for tracing both anti-
aging and anti-melanogenic effects. 
The age-related phenotype of senescence involves the attenuation of various organs. SOD1 
reacts with intracellular O2
-
 in the cytoplasm. Sod1
-/-
 mice exhibit various age-related organ 
phenotypes because of increased intracellular O2
- 
concentrations. Oxidative damage is among the 
major factors underlying senescence-related changes in various tissues and organs. In addition, 
Sod1 incompetence results in skin atrophy, which is associated with the decrease in extracellular 
matrix related-genes, such as Col1a1 and Has2 
24
. Therefore, Sod1
-/-
 mice constitute a suitable 
model for studying age-associated skin aging. Recently, I further established hairless Sod1
-/-
 
double-mutant mice to avoid variations in skin morphology during the hair cycle 
32
. Thus, these 
double-mutant mice will be a valuable mouse model for mimicking age-related skin thinning. In 
this context, the present study explored the feasibility of using natural antioxidant treatment to 
delay skin aging. I investigated the beneficial effects of Panax ginseng berry, which contains 
several bioactive compounds 
56-59
, as well as its bioactive compound SYR, on hairless Sod1-
deficient phenotypes.  
Among the senescence phenotypes of tissues, skin undergoes marked changes during aging. 
With senescence, the thickness of both the dermis and epidermis decrease considerably. In Sod1
-/-
 
mice, the thickness of the dermis was markedly decreased (Figure 11a and Figure 12-14). The 
attenuating effects of GB or SYR on skin atrophy were mediated by its antioxidative activity. 
SYR treatment reduced the levels of an oxidative stress marker and intracellular ROS (Figure 
11c, d). Because SYR activated fibroblast proliferation (Figure 11e) and given previous reports 
that ginseng extracts inhibit NF-κB signaling 45, I hypothesized that SYR also induces this 
signaling pathway. However, SYR did not affect NF-κB phosphorylation or procollagen 
expression (Figure 15a, b). Since collagen synthesis is a major factor in skin aging, SYR likely 
affects another pathway that regulates collagen homeostasis.  
Class O forkhead/winged helix (FoxO) transcription factors are critical regulatory factors of 
various biological events, including metabolism, growth, development, and longevity 
60,61
. FoxO 
factors are involved in cellular signaling and are activated by various environmental stimuli such 
as insulin, insulin growth factors (IGFs), oxidative stress, cytokines, and nutrients. In particular, 
oxidative stress inhibits or activates FoxO factors in a context-dependent manner. For instance, 
hydrogen peroxide inhibits FoxO activity by activating the phosphoinositide 3 kinase-protein 
kinase B pathway by exhibiting insulin-mimetic effects 
15
, whereas ROS-activated macrophage-
stimulating 1, mitogen-activated protein kinase, and c-Jun N-terminal kinase activate FoxO via 
phosphorylation and by disrupting 14-3-3 binding 
16,17
. In skin, FoxO3a down-regulation 
promotes cellular senescence in human dermal fibroblasts 
62
. In addition, FoxO3a regulates UVB 
protection, and its nuclear translocation is also regulated by UV irradiation 
63,64
. These studies 
suggest that FoxO3a plays an important role in cellular responses in the skin that are induced by 
external stimulation. In addition, previous reports suggest that reduced FoxO3a expression 
results in low autophagy in fibroblasts grown on a collagen matrix 
65
 and that FoxO3a promotes 
fibroblast proliferation on a type I collagen matrix 
66
. my previous studies indicated that SYR 
activates FoxO3a in cardiomyocytes 
67
, as well as in skin cells, fibroblasts and melanocytes. 
Therefore, I predict that the activation of FoxO3a by SYR results in the activation of collagen 
synthesis or the inhibition of degradation. Previously, Wang et al. reported that FoxO3a down-
regulates MMP-2 in smooth muscle cells 
48
. Initially, I examined whether FoxO3a 
phosphorylation was reduced in the SYR-treated group (Figure 15a, d and Figure 17). Then, I 
investigated MMP-1 and MMP-2 protein expression in mouse back skin. Interestingly, SYR 
strongly suppressed MMP-2 upregulation in Sod1
-/-
 mice but did not affect MMP-1 expression 
(Figure 16 and Figure 19). To uncover the molecular mechanism of SYR, I performed examined 
the expression of MMP-2 under w/o siFoxO3a condition in gene and protein level. The mmp-2 
gene expression was decreased by SYR treatment in Human dermal fibroblasts (HDFs) about 
41% however in siFoxO3a condition, SYR did not lowered mmp-2 expression significantly. SYR 
also declined MMP-2 protein expression and gelatinase activity about 60% and 51.8% 
respectively, in FoxO3a-dependent manner (Figure 20). Although these results did not explain 
molecular mechanism of SYR clearly, I suggest that the anti-aging effects of SYR in skin largely 
affected by FoxO3a activation. 
In conclusion, SYR treatment attenuates senescence-related skin atrophy in Sod1
-/-
 mice via 
FoxO3a activation. Activated FoxO3a results in the inhibition of collagen degradation by 
somehow suppressing MMP-2 expression. my results suggest that Sod1
-/-
 mice are a good model 
for studying age-related skin atrophy and that skin aging can be prevented by natural compounds. 
my findings imply that modulation of signaling for FoxO3a-mediated collagen biosynthesis, 
which is not yet fully defined, and that the use of FoxO3a activators may help prevent skin 
senescence. Overall, these studies suggest that FoxO3a activation may be a novel therapeutic 
strategy for the treatment and prevention of dermal aging. 
 
Materials and Methods 
Materials and administration 
MITF (C5), tyrosinase (H-109), TYRP-1 (H-90), DCT (C-9), GAPDH (FL-335), and Lamin B 
(C-5) antibodies were purchased from Santa Cruz Biotechnology. Antibodies against MITF 
(Noemarkers, Fremont, CA) and tyrosinase (Upstate biotechnology, Lake Placid, NY) were also 
used. FoxO3a (#9467), FoxO3a (75D8), FoxO1 (C29H4), FoxO4 (55D4), phospho-FoxO3a 
(#9466), Akt (#9272), and phosphor-Akt (#4060) antibodies were obtained from Cell Signaling 
Technology. The PI3K inhibitors LY294002 and wortmannin were obtained from Cell Signaling 
Technology. Akt inhibitor 1/2 (A6730) was purchased from Sigma. Secondary antibodies for 
western blot and immunofluorescence were obtained from Cell Signaling Technology and 
Invitrogen, respectively. Plasmids for HA-FoxO3a WT (1787) and NLS mutant, FLAG-FoxO3a 
TM (8361) were obtained from Addgene. FoxO3a validated stealth RNAi duopak and scramble 
RNAi were purchased from Invitrogen. 
[8R,8’R]-[+]-syringaresinol (HanChem Co., Ltd., Daejeon, Korea) or ginseng berry extract 
(provided by R&D Center of Amorepacific Corporation, Yongin, Korea, Lot number 1305) were 
suspended in MilliQ water. For the first trial, SYR (10 or 50 mg/kg/day) or ginseng berry extract 
(100 or 300 mg/kg/day) were administered orally via gavage to hairless Sod1
−/−
 mice (n = 11-13) 
at 6 weeks of age for 8 weeks. For the second trial, SYR (50 mg/kg/day) or ginseng berry extract 
(300 mg/kg/day) were administered orally via gavage to hairless Sod1
−/−
 mice (n = 8-10) at 16 
weeks of age for 8 weeks.  
 
Animals  
Hairless Sod1
−/−
 double-mutant mice constitute a valuable mouse model for mimicking age-
related skin thinning 
24
. Sod1
−/−
 mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME, USA) and backcrossed with C57BL/6NCrSlc mice (Japan SLC, Shizuoka, Japan) over ten 
generations. Hos:HR-1
hr/hr
 mice were purchased from Hoshino Laboratory Animals, Inc. (Ibaraki, 
Japan), and hairless Sod1
−/−
 double-mutant mice were generated by crossbreeding Hos:HR-1
hr/hr
 
with Sod1
−/−
 mice for five or six generations. In vivo analyses were performed using in vitro 
fertilization and embryonic transfer techniques to generate hairless Sod1
−/−
 and hairless Sod1
+/+
 
male mice. Genotyping of the Sod1
−/−
 allele was performed using genomic PCR with genomic 
DNA biopsied from the tail tips of mice at 3-4 weeks of age. The animals were housed under a 
12 h light/dark cycle and fed ad libitum MF chow (Oriental Yeast Co., Ltd., Tokyo, Japan). Male 
mice were separated from female mice at 3 weeks of age, and the housed cages were divided into 
groups based on the average body weights at one week before administration. The mice were 
maintained and studied according to protocols approved by the Animal Care Committee of Chiba 
University. 
 
Cell culture and growth activity assay 
MNT1 cells were maintained in Minimum Essential Media (Gibco) containing 10% Dulbecco's 
Modified Eagle’s Medium, 20 mM HEPES (Sigma), 20% fetal bovine serum, 100 U/mL 
penicillin G, and 100 μg/mL streptomycin sulfate. MNT1 cells were incubated at 37°C with 5% 
CO2 and regularly passaged at a density of 80% (1:8 ratio). Dermal fibroblasts from adult skin 
were purchased from Lonza (Walkersville, MD, USA) and maintained in DMEM supplemented 
with 1% penicillin/streptomycin and 10% heat-inactivated fetal bovine serum (FBS, Gibco, 
Carlsbad, CA, USA). The cells were cultured and regularly passaged at a density of 90% 
confluent. Cell proliferation and cytotoxicity were measured using cell counting kit-8 (Dojindo, 
Japan). 
 
Antioxidant activity assay  
The catalase activity was determined from the amount of the residual H2O2 as measured by a 
spectrophotometric method. Briefly, 800 L of 25 M H2O2 and 200 L of a sample solution in 
water that contained ginseng root extract, ginseng berry extract or syringaresinol were added to 
initiate the quenching reaction. After five min incubation, the concentration of H2O2 was 
measured at 240 nm. Water was used as a vehicle control, and the residual H2O2 is represented as 
a percentage of the control. 
The DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging activity was calculated from the 
residual DPPH concentration, as estimated by a spectrophotometric method (Yamazaki et al., 
1994). In brief, 500 L of 60 M DPPH was placed in a quartz cuvette, and same volume of a 
sample solution in ethanol that contained ginseng root extract, ginseng berry extract or 
syringaresinol were added to initiate the DPPH quenching. The quenching reaction was 
performed for thirty min incubation at room temperature (RT) and absorbance at 520 nm was 
measured using spectrometer. The residual DPPH is expressed as a percentage of the control and 
ethanol was used as a vehicle control. 
 
Tyrosinase enzymatic activity assay and determination of melanin levels  
To assess cellular tyrosinase activity, equal amounts of cell lysates (10 μg) were incubated with 
10 mM L-dihydroxyphenylalanine (L-DOPA) (pH 6.8) at 37°C for 1 h. Melanin synthesized 
from L-DOPA by tyrosinase in the cell extracts was measured at 490 nm in a UV-Vis 
spectrometer (Molecular Devices). Mushroom tyrosinase catalytic activity was measured by 
incubating 2 mg/mL mushroom tyrosinase (Sigma) with 10 mM L-DOPA solution supplemented 
with the reagents of interest at 37°C for 1 h. Melanin levels were measured at 490 nm. To 
measure cellular melanin levels, the cell pellets were dissolved in 1 N sodium hydroxide, and 
melanin levels were determined by measuring the absorbance at 490 nm. The melanin levels 
were normalized to protein input.  
 
Small interfering RNA and plasmid transfection 
MNT1 cells cultured in 60 mm dishes were transfected with stealth RNAi duopak FoxO3a (CAT 
No. 45-1712, Invitrogen), SignalSilence Akt siRNA (#6211, Cell Signaling Technology), and a 
Stealth RNAi
TM
 siRNA negative control kit (CAT No. 12935-100, Invitrogen) using 
Lipofectamine
TM
 RNAi MAX (Invitrogen) and 5 nM siRNA for 48 h, according to the 
manufacturer’s instructions. MNT1 cells (3.5  105 cells/6 wells) were grown to 60-70% 
confluence and then transfected with 4 μg of plasmid. The plasmids included constitutively 
active HA-FoxO (1787, Addgene) and constitutively active FoxO3a NLS mutant, FLAG-
FoxO3a TM (8367, Addgene).  
 
FoxO localization assay using immunofluorescence 
MNT1 cells were treated with each reagent (Vc, NAC, and Trolox) for 4 days, washed with PBS, 
fixed for 30 min in 4% paraformaldehyde, washed again, and incubated for 10 min in 0.1% 
Triton X-100. The cells were washed three times in PBS and incubated with anti-FoxO3a (1:200) 
or anti-FoxO1 antibodies (1:200) diluted in Hank’s solution (0.44 mM KH2PO4, 5.37 mM KCl, 
0.34 mM Na2HPO4, 136.89 mM NaCl, and 5.55 mM D-glucose) at 4C overnight. Secondary 
antibodies (Alexa Fluor 555- or Alexa Fluor 488-conjugated goat anti-rabbit or -mouse) were 
added for 1 h at room temperature. After washing, the coverslips were mounted onto glass slides 
and visualized using an EVOSfl digital fluorescence microscope (Advanced Microscopy Group) 
(Ex: 555 nm; Em: 565 nm for FoxO3a, Ex: 488 nm; Em: 519 nm for FoxO1).  
 
Cellular fractionation assay 
Cytoplasmic and nuclear fractions were prepared according to a previously published protocol 
(Schreiber et al., 1989). Briefly, the cells were lysed in a cytosolic lysis buffer containing 10 mM 
HEPES (pH 7.9), 10 mM KCl, 0.1 mM EGTA, 0.1 mM EDTA, 10% NP-40, 0.5 mM PMSF, 1 
mM DTT, and protease inhibitors. The nuclei were pelleted via a short centrifugation step and 
lysed in a nuclear buffer containing 20 mM HEPES (pH 7.9), 400 mM NaCl, 1 mM EGTA, 1 
mM EDTA, 1 mM PMS, 1 mM DTT, and protease inhibitors. The nuclear pellets were subjected 
to three freeze-thaw cycles before they were sonicated and centrifuged to obtain a solubilized 
nuclear fraction. 
 
Western blot analysis 
MNT1 cells were lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 
mM DTT, 0.5% NP-40, 25 mM β-glycerophosphate, 1 mM sodium orthovanadate, 0.5 mM 
PMSF, and a protease inhibitor cocktail (Protease inhibitor, Sigma) and incubated with the 
appropriate antibodies for 1 h. This incubation was followed by the addition of pre-cleared 
protein G beads (GE Healthcare) overnight at 4°C. Next, the beads were washed five times with 
lysis buffer. Western blotting was performed following standard protocols. The cell lysates (20 
g protein) were boiled in SDS sample buffer and resolved using 4-12% SDS-PAGE. The 
proteins were then transferred to a PVDF membrane (Invitrogen) and probed using specific 
antibodies. 
Mouse skin tissues were homogenized in 5 volumes (w/v) of RIPA buffer (25 mM Tris-HCl, pH 
7.5, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, and 0.1% sodium dodecylsulfate) 
supplemented with protease and phosphatase inhibitor cocktails (Roche Diagnostics, Tokyo, 
Japan). The protein concentrations of the homogenates were determined using the DC Protein 
Assay Kit. Proteins (20-40 μg/lane) were separated on a 6.5-10% polyacrylamide gel with 
Laemmli buffer and transferred to a PVDF membrane (0.4 μm pore size, Immobilon-P, Millipore, 
Germany) using a Transblot Turbo (Bio-Rad, Hercules, CA, USA) with Rapid Transfer buffer 
(Amresco, Solon, OH, USA, N789, 25 V for 30 min) for total FoxO3a or with Towbin buffer (25 
mM Tris, 192 mM glycine) without methanol (20 V for 40 min or 25 V for 30 min) for other 
proteins. For the detection of transcription factors, the membrane was blocked with 3% bovine 
serum albumin (Nacalai Tesque, Kyoto, Japan) in TBST (TBS containing 0.01% Tween-20) for 1 
h at room temperature. The membrane was blocked with 5% skim milk for all other proteins. The 
following primary antibodies were used overnight at 4°C: anti-MMP-1 (Abbiotech, CA, USA, 
#250750 dilution factor 1:200), anti-MMP-2 (Novus Biologicals, CO, USA, NB200-193 dilution 
factor 1:1000), anti-FoxO3A [75D8] (Cell Signaling, Tokyo, Japan, #2497 dilution factor 1:100), 
anti-phosphorylated FoxO3A [EPR1951(2)] (Abcam, MA, USA, ab154786 dilution factor 1:500), 
anti-NF-κB/p65 [D14E12] (Cell Signaling, #8242 dilution factor 1:500), anti-phosphorylated 
NF-κB/p65 [93H1] (Cell Signaling, #3033 dilution factor 1:500), anti-α-tubulin (Cell Signaling, 
#2144 dilution factor 1:1000), and anti-GAPDH [14C10] (Cell Signaling, #2118 dilution factor 
1:1000). The membrane was then treated with secondary antibody (Cell Signaling, #7074 
dilution factor 1:2000) and Clarity Western ECL (Bio-Rad, #1705060) at room temperature 
according to the manufacturer’s protocols, followed by detection using an LAS-3000 (Fujifilm, 
Tokyo, Japan).  
 
RT-qPCR 
MNT1 cells were homogenized in TRIzol reagent (Gibco), and total RNA was extracted 
according to a standard protocol. Total RNA (4 μg) was reverse-transcribed using random 
hexamers and SuperScript III (Invitrogen) according to the manufacturer’s instructions. 
Quantitative PCR was performed using the ABI 7500 Fast Real-Time PCR System with Taqman 
Universal Master Mix II (Applied Biosystems) and TaqMan site-specific primers and probes 
(Applied Biosystems). I used the CT analysis method 
68
; the efficiency of the target and the 
reference amplification were approximately equal. Reactions were performed in triplicate and 
mRNA expression levels were quantified using the relative CT method and normalized to 
GAPDH level. 
Total RNA was extracted from back skin using the RNAlater and the TRIzol reagent (Thermo 
Fisher Scientific, Carlsbad, CA, USA) according to the manufacturer’s instructions 19. cDNA 
was synthesized from 1 µg of total RNA using ReverTra Ace qPCR RT Master Mix (Toyobo, 
Osaka, Japan). Real-time PCR was performed on a MiniOpticon (Bio-Rad) with the 
SsoAdvanced SYBR Green Supermix (Bio-Rad) according to the manufacturer’s protocols. All 
data were normalized to the level of the housekeeping gene glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) or ribosomal RNA 18S (Rn18S). The following primers were used for 
the analysis: Gapdh, forward, 5’-ATG TGT CCG TCG TGG ATC TGA-3’, and reverse, 5’-TGC 
CTG CTT CAC CAC CTT CT-3’; Col1a1, forward, 5’-CAT GTT CAG CTT TGT GGA CCT-3’, 
and reverse, 5’- GCA GCT GAC TTC AGG GAT GT-3’; Mmp-1a, forward, 5’-TGT GTT TCA 
CAA CGG AGA CC-3’, and reverse, 5’-GCC CAA GTT GTA GTA GTT TTC CA-3’; Mmp-2, 
forward, 5’-TAA CCT GGA TGC CGT CGT-3’, and reverse, 5’-TTC AGG TAA TAA GCA CCC 
TTG AA-3’; Il-6, forward, 5’-GCT ACC AAA CTG GAT ATA ATC AGG A-3’, and reverse, 5’-
CCA GGT AGC TAT GGT ACT CCA GAA-3’; Rn18S, forward, 5’-GTA ACC CGT TGA ACC 
CCA TT-3’, and reverse, 5’-CCA TCC AAT CGG TAG TAG CG-3’; and Sirt1, forward, 5’-CAG 
TGA GAA AAT GCT GGC CTA-3’, and reverse, 5’-TTG GTG GTA CAA ACA GGT ATT GA-
3’.  
 
Lipofuscin accumulation  
Dermal fibroblasts from adult skin were cultured with each reagent for 10 passages (3-4 days per 
1 passage), washed with PBS, and fixed in 4% paraformaldehyde for 30 min. The cells were then 
washed and incubated in 0.1% Triton X-100 for 10 min. After washing, the cover slips were 
mounted onto glass slides and visualized by a confocal laser scanning microscope (LSM7, Carl 
Zeiss) (with an excitation wavelength at 350 nm and an emission wavelength at 420 nm). The 
fluorescence intensities of the cells were measured densitometrically with the ZEN Lite software 
(Carl Zeiss) by calculating the average pixel intensity in each cell. The significance of the 
differences among the control and experimental groups were analyzed using a one-way ANOVA. 
 
Histology  
For histological observations, skin specimens obtained from the backs of the mice were dissected 
and fixed overnight in a 20% formalin neutral buffer solution (Wako, Osaka, Japan). Then, the 
specimens were embedded in paraffin and sectioned on a microtome at a thickness of 4 μm using 
standard techniques 
24
. Skin tissue thickness (epidermis and dermis) was measured in 
hematoxylin and eosin-stained sections using the Leica QWin V3 imaging software program 
(Leica, Germany). For immunohistochemistry, deparaffinized sections were autoclaved at 95°C 
in 10 mM citric acid and 0.05% Tween 20, pH 6.0, for 30 min and then treated with 3% H2O2 in 
PBS(-) at room temperature for 30 min. After being blocked with 3% goat serum in PBS(-), the 
sections were incubated overnight at 4°C with anti-MMP-1 (Abbiotech, CA, USA, #250750 
dilution factor 1:300), anti-MMP-2 (Novus Biologicals, CO, USA, NB200-193 dilution factor 
1:300), and anti-phosphorylated FoxO3A (Abcam, MA, USA, ab154786 dilution factor 1:50) 
antibodies. Immunoreactivity was visualized using a VECTASTAIN ABC Elite kit (Vector 
Laboratories, CA, USA) with biotinylated anti-rabbit antibody according to the manufacturer’s 
protocols, followed by staining with 0.05% diaminobenzidine, 50 mM Tris-HCl, and 0.1% H2O2, 
pH 7.5. The sections were counterstained with Meire’s hematoxylin (Wako, Osaka, Japan).  
 
Measurement of oxidative stress markers  
To measure 8-isoprostane content, blood was collected from the left ventricular space into 
EDTA-coated collection tubes (Terumo, Tokyo, Japan) and centrifuged at 6,000 rpm for 5 min at 
room temperature. Plasma was separated from clotted blood and added to 100 μM indomethacin 
and 50 g/ml dibutylhydroxytoluene (BHT, Wako). The back skin tissues of male mice were 
homogenized with 0.1 M phosphate buffer, pH 7.4, containing 1 mM EDTA (Dojindo 
Laboratories, Kumamoto, Japan) and 50 μg/ml BHT. The homogenate was centrifuged at 
8,000 × g for 10 min at 4°C, and the total supernatant was used for the assay. The 8-isoprostane 
level was measured using the 8-isoprostane EIA Kit (Cayman Chemical Company, Arbor, MI, 
USA) according to the manufacturer’s instructions. The skin supernatant was also assayed for the 
protein concentration using the DC Protein Assay Kit (Bio-Rad, Hercules, CA, USA), and 8-
isoprostane levels were normalized to protein levels. For measuring of the intracellular ROS, 
skin tissues were dissected from Sod1
+/+
 and Sod1
−/−
 mouse neonates at 5 days of age. Primary 
dermal fibroblasts were isolated by dissociation in 0.2% collagenase type 2 (Worthington 
Biochemical Corporation Lakewood, NJ, USA) at 37°C for 60 min. Cells were cultured in α-
MEM (Thermo Fisher Scientific, Carlsbad, CA, USA) supplemented with 20% fetal bovine 
serum (FBS), 100 unit/ml penicillin, and 0.1 mg/ml streptomycin at 37°C in a humidified 
incubator with 5% CO2 and 1% O2 to prevent damage by oxygen and to maintain the viability of 
Sod1
−/−
 fibroblasts. During the subsequent experiments, the cells were cultured to investigate 
cellular phenotypes under a general condition (20% O2). The fibroblasts were cultured in 12-well 
culture plates (Falcon BD, Franklin Lakes, NJ, USA) with or without 50 µM SYR for 72 h and 
then incubated with 10 µM CM-H2DCFDA (DCF, Thermo Fisher Scientific, Carlsbad, CA, 
USA) for 30 min at 37°C. After incubation, cells were trypsinized and resuspended in PBS(-). 
Fluorescence intensity was assessed using a flow cytometer (BD FACSCanto II, BD Biosciences, 
Franklin Lakes, NJ, USA). 
 
Outgrowth assay  
Adult Sod1
+/+
 and Sod1
−/−
 mouse back skin was sterilized with 70% ethanol, rinsed with PBS 
(Takara Bio Inc., Shiga, Japan) and punched out into discs measuring 5 mm in diameter using a 
dermal punch (Nipro, Tokyo, Japan) 
19
. The punched skin discs were placed into a 24-well 
culture plate (Falcon BD, Franklin Lakes, NJ, USA) and cultured with or without 50 µM SYR in 
α-MEM containing 20% FBS, 100 units/mL penicillin, and 0.1 mg/ml streptomycin at 37°C in a 
humidified incubator with 5% CO2 and 20% O2. The number of outgrowing fibroblasts that 
originated from the mouse skin discs was directly counted at 96 h after culture. 
Statistical analysis 
Statistical analyses were performed using Student’s t-test for comparisons between two groups 
and one-way analysis of variance (ANOVA) with Dunnett's multiple comparisons test for 
comparisons among three groups when comparing dose responses. Differences were considered 
significant when the P values were less than 0.05. All data are expressed as the mean ± standard 
deviation (SD). 
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 Figure 1. The FoxO proteins expression level and the melanogenesis regulation by FoxO3a in primary 
melanocytes. (a) The melanin levels were visualized after dissolving cell pellets with 1 N NaOH in lightly 
pigmented (LP), moderately pigmented 
37
, and darkly pigmented (DP) melanocytes and MNT1 cells. (b) The 
FoxO1, FoxO3a, and FoxO4 mRNA expression levels of in the LP, MP, and DP melanocytes and MNT1 cells. 
The data represent mean ± S.D. from three independent experiments. (c) The FoxO proteins expression levels 
in pigmented cells were determined by western blot analysis. (d) PI3K inhibitors LY294002 (500 μM) or 
wortmannin (1 μM) treated in primary melanocytes for 48 h. The cells were stained with an anti-FoxO3a 
antibody (FoxO3a; red) and DAPI (nucleus; blue). Cell with FoxO3a localization were counted and depicted 
by EVOSfl digital fluorescence microscope. Representative images are shown. Control, vehicle alone-treated; 
Ph, phase-contrast image. Scale bars, 200 μm. (e) Melanin levels were visualized under PI3K inhibitors 
LY294002 (500 μM) and wortmannin (1 μM) treatment in primary melanocytes for 5 days. The quantitative 
melanin levels were determined by a spectrophotometer with absorbance at 490 nm. (f) LY294002 (500 μM) 
or wortmannin (1 μM) treated in primary melanocytes for 48 h, and then the cell lysates were analyzed by 
western blotting analysis. Control: vehicle alone-treated.  
  
 
Figure 2. Melanogenesis regulation by FoxO3a is induced by melanogenic genes 
modulation. FoxO3a siRNAs were transfected in MNT1 cells for 48 h. Down-regulated (a) or 
up-regulated (b) genes were estimated via RT-qPCR. *p < 0.05. (c) The cell lysates were 
analyzed via western blot after FoxO3a siRNAs treatment. The melanin levels (d, e) and 
tyrosinase activity (f) were measured using a spectrophotometer at 490 nm. Control: untreated; 
Mock: control siRNA; si-1, 2: siRNA against FoxO3a. The values of three independent 
experiments are presented (mean ± S.D.). *p < 0.05. 
  
 
Figure 3. The regulation of FoxO3a expression affects melanogenesis-related genes. Down-
regulated (a) or up-regulated (b) genes following FoxO3a siRNA treatment (si-1 or -2) are 
shown. *p < 0.05. Down-regulated (c) or up-regulated (d) genes after treatment with the PI3K 
inhibitors LY294002 and wortmannin are displayed. *p < 0.05. 
 
 Figure 4. FoxO3a regulates melanogenesis by its nuclear translocation. (a) The melanin levels visualized in MNT1 cells 
under treatment with the PI3K inhibitors LY294002 (500 μM) and wortmannin (1 μM) for 48 h. The quantitative melanin levels 
(b) and tyrosinase activity (c) were measured by a spectrophotometer at 490 nm. The down-regulated (d) and up-regulated (e) 
genes are shown via RT-qPCR after the treatment with the PI3K inhibitors. *p < 0.05. The data are presented from three 
independent experiments (mean ± S.D.). (f) The proteins, including FoxO3a, were analyzed via western blot analysis in cytosolic 
and nuclear cell fractionation after PI3K inhibitor treatment. Lamin B was used as a marker of the nuclear fraction. C, untreated; 
M, vehicle alone-treated; Ly, LY294002; Wort, wortmannin. (g) The wild-type FoxO3a (WT) or mutants FoxO3a with a deleted 
nuclear localization signal (NLS) constructs were designed and transfected into MNT1 cells. FoxO3a protein expression was 
analyzed by western blot in cytosolic and nuclear portions of total protein. NT, non-treated; WT, wild-type; NLS, nuclear 
localization signal deleted mutant. (h) The MNT1 cells were transfected with overexpression of the wild-type or mutant FoxO3a, 
then melanin were visualized. The siRNAs against FoxO3a or Akt was treated in MNT1 cells; 10 μM Akt inhibitor was treated 
for 48 h. The melanin levels (i), and the protein levels (j) of each protein were analyzed. Con: vehicle alone-treated; Mock: 
control siRNA. (k) MNT1 cells were transfected with FoxO3a or Akt siRNAs; the treatment of 10 μM Akt inhibitor was 
performed for 48 h. The cells were stained with an anti-FoxO3a antibody (FoxO3a; red) and DAPI (nucleus; blue). The 
representative images were acquired using fluorescence microscopy. Ph, phase-contrast image. Scale bars, 200 μm. Cell with 
FoxO3a localization were counted and depicted by EVOSfl digital fluorescence microscope. 
  
 
Figure 5. Antioxidants reduce melanogenesis and especially inhibit tyrosinase and DCT. (a) 
The melanin levels (upper panel) and tyrosinase activity (lower panel) is shown after the 
treatment with each antioxidant at various concentrations for 48 h. The melanogenesis–related 
genes expression levels, mRNA (b) and protein (c) were analyzed via RT-qPCR after the 
treatment with each antioxidant (100 nM) for 48 h. *p < 0.05. Con: vehicle only; Vc: vitamin C; 
NAC: N-acetyl cysteine. The data are represented by three independent experiments (mean ± 
S.D.).  
 
  
Figure 6. The effects of antioxidants on tyrosinase activity, cell proliferation, and cell 
cytotoxicity. (a) Mushroom tyrosinase was treated with 1 nM – 100 μM of each antioxidant in 
vitro. Cell proliferation (b) and cytotoxicity (c) were analyzed by cell quantification and MTT 
assay, respectively, after treatment with each antioxidant. Vc, Vitamin C; NAC, N-Acetylcysteine. 
 
  
 
Figure 7. The nuclear translocation of FoxO3a is dependent on antioxidant concentrations. 
Nuclear translocation of FoxO3a after treatment with various concentrations of Vc (a), NAC (b), 
or Trolox (c) was detected via immunofluorescence using an anti-FoxO3a antibody. Ph, phase-
contrast image; DAPI, blue; FoxO3a, red; and merged images are presented. Scale bars, 100 μm. 
 
 Figure 8. FoxO3a nuclear translocation is induced by antioxidants treatment. (a) The cells 
were stained with an anti-FoxO3a antibody (FoxO3a; red) and DAPI (nucleus; blue) after 
antioxidants (100 nM) treatment for 48 h. The representative images were acquired by 
fluorescence microscopy. Ph, phase-contrast image. Scale bars, 100 μm. Cell with FoxO3a 
localization were counted and depicted by EVOSfl digital fluorescence microscope. (b) After the 
treatment with each antioxidant, total FoxO3a protein was analyzed by western blot. (c) FoxO3a 
was examined via western blot in cytosolic and nuclear fractions of MNT1 cells under treatment 
with 100 nM of each antioxidant for 48 h. (d) 100 nM of vitamin C was treated in MNT1 cells 
for 2, 6, 24, or 48 h and then cellular fractionation was performed. FoxO3a was detected in 
cytosolic and nuclear fractions by western blot. Con: vehicle only; Vc: vitamin C; NAC: N-
acetyl cysteine. GAPDH or lamin B was used as a marker of the cytosolic fraction or nuclear 
fraction, respectively. 
  
Figure 9. FoxO1 nuclear translocation was not affected by antioxidant treatment. The 
nuclear translocation of FoxO1 after treatment with each antioxidant (100 nM) was examined via 
immunofluorescence using an anti-FoxO1 antibody. Ph, phase-contrast image; DAPI, blue; 
FoxO3a, green; and merged images are presented. Scale bars, 100 μm. 
 
  
Figure 10. Regulation of melanin synthesis by antioxidant and PI3K mediates FoxO3a. (a-
c) 100 nM of each antioxidant and a 0-100 μM dose range of vitamin C (d), or PI3K inhibitors 
(e) was treated in MNT1 cells after FoxO3a siRNAs were applied. The melanin levels (a, b, d, 
and e) and the tyrosinase activity (c) was determined. Con: vehicle alone; Mock: control siRNA; 
si: siRNA against FoxO3a; Vc: vitamin C; NAC: N-acetyl cysteine. The data are shown as the 
mean ± S.D. of three independent experiments. *p < 0.05. 
 
 Figure 11. SYR attenuates skin atrophy and oxidative damage in Sod1
−/−
 mice. (a) Hematoxylin and eosin 
staining of the back skin of Sod1
−/−
 and Sod1
+/+
 mice orally treated with SYR (50 mg/kg/day) for 8 weeks 
between 16 to 24 weeks of age. (b) The thicknesses of the total back skin layers of the knockout and wild-type 
mice orally treated with SYR (50 mg/kg/day) for 8 weeks from 16 to 24 weeks of age. (n = 9–10). (c) Absolute 
8-isoprostane levels in the back skin of Sod1
−/−
 and Sod1
+/+
 mice orally treated with SYR (50 mg/kg/day) for 8 
weeks between 16 to 24 weeks of age. (n = 9–10). (d) Relative intracellular ROS levels in primary Sod1
−/−
 and 
Sod1
+/+
 fibroblasts treated with 50 M SYR for 72 h, as measured using 2’,7’-dichlorodihydrofluorescein 
(DCF) (n = 3). (e) Number of outgrown fibroblasts in Sod1
−/−
 and Sod1
+/+
 skin disc cultures treated with 50 
M SYR for 72 h (n = 6–8). The statistical evaluations were performed using Dunnett’s or Student’s t-tests. 
Data represent the mean ± SD; 
*
p < 0.05. The scale bar represents 100 m.  
 
 
 
Figure 12. Effects of syringaresinol on skin atrophy. (a) Hematoxylin and eosin staining of the 
back skin of hairless Sod1
−/−
 (knockout) and hairless Sod1
+/+
 (wild type) mice orally treated with 
syringaresinol (SYR, 10 or 50 mg/kg/day) for 8 weeks between 6 to 14 weeks of age. (b) The 
thicknesses of the total back skin layers of Sod1
−/−
 and Sod1
+/+
 mice orally treated with SYR (10 
or 50 mg/kg/day) for 8 weeks from 6 to 14 weeks of age. (n = 12–13). The statistical evaluations 
were performed using ANOVA Dunnett’s test. Data represent the mean ± SD; *p < 0.05. The 
scale bar represents 100 m. 
 
 
 
Figure 13. Effects of ginseng berry on skin atrophy and oxidative damage in SOD1 
knockout mice. (a) Hematoxylin and eosin staining of the back skin of hairless Sod1
−/−
 
(knockout) and Sod1
+/+
 (wild type) mice orally treated with the ginseng berry (GB, 100 or 300 
mg/kg/day) for 8 weeks between 6 to 14 weeks of age. (b) The thickness of total skin area of the 
back skin of the Sod1
−/−
 and Sod1
+/+
 mice orally treated with GB (100 or 300 mg/kg/day) for 8 
weeks from 6 to 14 weeks of age. (n = 12–13). The statistical evaluations were performed using 
ANOVA Dunnett’s test. Data represent the mean ± SD; *p < 0.05. The scale bar represents 100 
m. 
 
 
 
Figure 14. Effects of syringaresinol and ginseng berry on skin atrophy in SOD1 knockout 
mice. Hematoxylin and eosin staining of the back skin of hairless Sod1
−/−
 (knockout) and 
Sod1
+/+
 (wild type) mice orally treated with the SYR (50 mg/kg/day) or GB (300 mg/kg/day) 
for 8 weeks between 16 to 24 weeks of age (n = 4). The scale bar represents 100 m.  
 
 Figure 15. SYR decreases phosphorylation of FoxO3a, but not NF-κB, in Sod1−/− skin. (a) Western blotting of 
total NF-κB, phosphorylated NF-κB, total FoxO3a, and phosphorylated FoxO3a levels in the back skin of Sod1−/− 
and Sod1+/+ mice orally treated with SYR (50 mg/kg/day) for 8 weeks between 16 to 24 weeks of age. Full blotting 
data presented in Supplematary Figure S7. The mRNA levels of the NF-κB downstream genes procollagen 
1a1/Col1a1 (b) and interleukin-6/Il-6 (c) in the back skin of Sod1−/− and Sod1+/+ mice orally treated with SYR (50 
mg/kg/day) for 8 weeks between 16 to 24 weeks of age. The data were normalized to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase/Gapdh expression (n = 4 each group). (d) Immunohistochemical 
staining for phosphorylated FoxO3a was performed on the back skin sections prepared from Sod1−/− and Sod1+/+ 
mice orally treated with SYR (50 mg/kg/day) for 8 weeks between 16 to 24 weeks of age. The statistical evaluations 
were performed using Student’s t-test. Data represent the mean ± SD; *p < 0.05. The scale bar represents 100 m.  
 
Figure 16. SYR normalizes MMP-2 expression in Sod1
−/−
 skin. (a) Immunohistochemical staining for MMP-1 
and MMP-2 in back skin sections prepared from Sod1−/− and Sod1+/+ mice orally treated with SYR (50 mg/kg/day) 
for 8 weeks between 16 to 24 weeks of age. Western blotting bands (b) and graphic presentations (c) of MMP-1 and 
MMP-2 levels in the back skin of Sod1−/− and Sod1+/+ mice orally treated with SYR (50 mg/kg/day) for 8 weeks 
between 16 to 24 weeks of age. Full blotting data presented in Supplementary Figure S7. (d) mRNA expressions of 
Mmp-1a and Mmp-2 in the back skin of Sod1−/− and Sod1+/+ mice orally treated with SYR (50 mg/kg/day) for 8 
weeks between 16 to 24 weeks of age. The data were normalized to the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase/Gapdh expression (n = 4 each group). The statistical evaluations were performed using 
Student’s t-test. Data represent the mean ± SD; *p < 0.05. The scale bar represents 100 m.  
 
Figure 17. Syringaresinol treatment inhibits the phosphorylation of FoxO3a in mouse skin. 
The immunohistochemical staining of phosphorylated FoxO3a was subjected on the back skin 
sections prepared from Sod1
−/−
 and Sod1
+/+
 mice orally treated with the SYR (50 mg/kg/day) for 
8 weeks between 16 to 24 weeks of age (n = 4). These sections were counterstained with 
hematoxylin. The scale bar represents 100 m.  
 
 
 
 
 
Figure 18. The expressions of Sirt1/Gapdh (a) and Sirt1/Rn18S (b) in the back skin of Sod1
−/−
 
and Sod1
+/+
 mice orally treated with the SYR (50 mg/kg/day) for 8 weeks between 16 to 24 
weeks of age. These data indicates that any significations were not observed.  
 
 
  
 
Figure 19. FoxO3a activation by syringaresinol associates with suppression of MMP-2 
expression. The immunohistochemical staining of MMP-2 was subjected on the back skin 
sections prepared from Sod1
−/−
 and Sod1
+/+
 mice orally treated with the SYR (50 mg/kg/day) 
for 8 weeks between 16 to 24 weeks of age (n = 4). These sections were counterstained with 
hematoxylin. The scale bar represents 100 m.  
 
 
 
 
Figure 20. SYR lowered MMP-2 expression and also gelatinase activity in FoxO3a-
dependent manner. Human dermal fibroblasts were transfected with small interfering RNAs 
(siRNAs) against FoxO3a for 48 hours. (a) The expressions of foxo3a and mmp-2 genes were 
analyzed by means of quantitative real-time reverse transcriptase PCR (RT-qPCR). *P < 0.05. (b) 
After treatment with FoxO3a siRNAs and 500 nM SYR for 2 days, the cell lysates were analyzed 
by western blot analysis. (c-d) The MMP-2 gelatinase activity of cell lysates was measured by 
gelatinase fluorogenic assay kit at an excitation wavelength of 320 nm and an emission 
wavelength of 405 nm. *P < 0.05. 
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